CervoMed prices unregistered $10.5 million private placement at $3.14 per unit

CervoMed Inc.

CervoMed Inc.

CRVO

0.00
  • CervoMed priced an unregistered private placement expected to raise about USD 10.5 million in upfront gross proceeds.
  • Deal sells 3,360,377 units at USD 3.14 per common-share unit, or USD 3.139 per pre-funded-warrant unit.
  • Each unit includes common stock or a pre-funded warrant, one Series B warrant, one Series C warrant.
  • Warrants could add up to about USD 21.7 million if fully exercised for cash; Series B strike USD 3.32, Series C strike USD 3.14.
  • Proceeds extend cash runway into Q2 2027; funding supports partnering to advance neflamapimod into Phase 3 in dementia with Lewy bodies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606100730PRIMZONEFULLFEED9734701) on June 10, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.